[{"orgOrder":0,"company":"VeraMorph","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"VeraMorph","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VeraMorph \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"VeraMorph \/ National Cancer Institute"}]

Find Clinical Drug Pipeline Developments & Deals by VeraMorph

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : The funding will support the development of Fulvestrant for estrogen receptor positive metastatic breast cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 15, 2025

                          Lead Product(s) : Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : National Cancer Institute

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank